ACTONEL WITH CALCIUM (COPACKAGED) Drug Patent Profile
✉ Email this page to a colleague
When do Actonel With Calcium (copackaged) patents expire, and when can generic versions of Actonel With Calcium (copackaged) launch?
Actonel With Calcium (copackaged) is a drug marketed by Warner Chilcott and is included in one NDA.
The generic ingredient in ACTONEL WITH CALCIUM (COPACKAGED) is calcium carbonate; risedronate sodium. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium carbonate; risedronate sodium profile page.
Summary for ACTONEL WITH CALCIUM (COPACKAGED)
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ACTONEL WITH CALCIUM (COPACKAGED) at DailyMed |
-patent-expirations.png "ACTONEL WITH CALCIUM (COPACKAGED) drug patent expirations")
Anatomical Therapeutic Chemical (ATC) Classes for ACTONEL WITH CALCIUM (COPACKAGED)
US Patents and Regulatory Information for ACTONEL WITH CALCIUM (COPACKAGED)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott | ACTONEL WITH CALCIUM (COPACKAGED) | calcium carbonate; risedronate sodium | TABLET;ORAL | 021823-001 | Aug 12, 2005 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACTONEL WITH CALCIUM (COPACKAGED)
International Patents for ACTONEL WITH CALCIUM (COPACKAGED)
See the table below for patents covering ACTONEL WITH CALCIUM (COPACKAGED) around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 027158 | FORMA DE DOSIFICACION ORAL PARA SER SUMINISTRADA AL ESTOMAGO, DICHA FORMA DE DOSIFICACION COMPRENDE UNA CANTIDAD SEGURA Y EFECTIVA DE UN INGREDIENTE ACTIVO Y EXCIPIENTES FARMACOLOGICAMENTE ACEPTABLES | ⤷ Try a Trial |
| Canada | 2293815 | COMPRIME A ENROBAGE PELLICULAIRE A INNOCUITE ACCRUE A L'EGARD DU TRACTUS OESO-GASTRO-DUODENAL (FILM-COATED TABLET FOR IMPROVED UPPER GASTROINTESTINAL TRACTSAFETY) | ⤷ Try a Trial |
| Canada | 2294595 | INHIBITION DE RESORPTION OSSEUSE (INHIBITING BONE RESORPTION) | ⤷ Try a Trial |
| Japan | S61210033 | PHARMACOLOGICAL COMPOSITION CONTAINING GEM-DIPHOSPHONATE | ⤷ Try a Trial |
| Norway | 941894 | ⤷ Try a Trial | |
| United Kingdom | 9819243 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ACTONEL WITH CALCIUM (COPACKAGED)
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | 300962 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721 |
| 0247633 | 62/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
| 1175904 | C01175904/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: SCHERING CORPORATION, US |
| 0933372 | 13/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713 |
| 0720599 | CR 2014 00050 | Denmark | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| 0933372 | PA2008006 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
